New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety of the fixed combination asthma
drug FlutiForm HFA MDI (containing fluticasone propionate and formoterol fumarate) in adult
and adolescent patients with mild to moderate-severe asthma.